Evaluating the safety and long-term efficacy of triple vasodilator therapy for pulmonary arterial hypertension associated with congenital heart disease
Event: ESC Congress 2023
Topic: Pharmacotherapy
Session: Pharmacotherapy and biomarkers in adult congenital heart disease: do the same rules apply?
Impact of triple vasodilator therapy on prognosis stratification of pulmonary arterial hypertension associated with congenital heart disease
Event: ESC Congress 2023
Topic: Pharmacotherapy
Session: Risk assessment in pulmonary hypertension: still a hot topic
Pulmonary artery aneurysm in pulmonary arterial hypertension associated with congenital heart disease
Event: ESC Congress 2023
Topic: Adult Congenital Heart Disease (ACHD)
Session: Insights into long-term follow-up of congenital heart disease
The patient with Down syndrome and pulmonary arterial hypertension associated with congenital heart disease: from childhood to adulthood
Event: ESC Congress 2022
Topic: Adult Congenital Heart Disease (ACHD)
Session: Determinants of survival and morbidity in patients with congenital heart disease
Added prognostic value of cardiopulmonary test variables in low-risk pulmonary artery hypertension patients
Event: ESC Congress 2022
Topic: Diagnostic Methods
Session: Risk stratification in acute PE: who does not care does not know
Is bilateral lung transplantation in pulmonary artery hypertension related to congenital heart disease a real therapeutic option? Experience of a national referral centre
Event: ESC Congress 2022
Topic: Surgery
Session: Surgery and intervention in congenital heart disease: moving forward
An electrocardiographic diagnostic model for differentiating right from left ventricular outflow tract arrythmias origin
Event: ESC Congress 2021 - The Digital Experience
Topic: Electrocardiography (ECG)
Session: Congress committee e-posters choice in arrhythmias and device therapy
ESC 365 is supported by
